Health Care [ 9/12 ] | Pharmaceuticals [ 36/76 ]
NASDAQ | Common Stock
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs.
It develops HT-001, a topical formulation in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; and HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases.
The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus.
The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003.
Hoth Therapeutics, Inc. was incorporated in 2017 and is headquartered in New York, New York.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 9, 24 | -0.24 Increased by +57.69% | -0.43 Increased by +44.19% |
| May 14, 24 | -0.46 Increased by +83.92% | -0.43 Decreased by -6.98% |
| Mar 28, 24 | -0.32 Increased by +88.81% | -0.51 Increased by +37.25% |
| Nov 13, 23 | -0.60 Increased by +70.73% | -0.72 Increased by +16.67% |
| Aug 11, 23 | -0.57 Increased by +74.79% | -1.16 Increased by +51.10% |
| Jun 14, 23 | -2.86 Decreased by -4.00% | -2.29 Decreased by -24.89% |
| Mar 31, 23 | -2.86 Increased by +18.29% | -2.29 Decreased by -24.89% |
| Nov 10, 22 | -2.05 Increased by +41.43% | -2.39 Increased by +14.23% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 24 | 0.00 Decreased by N/A% | -1.63 M Increased by +12.84% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -2.04 M Increased by +6.14% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 59.54 K Increased by +N/A% | -1.70 M Increased by +55.49% | Decreased by -2.86 K% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -2.09 M Increased by +19.87% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -1.87 M Increased by +38.70% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -2.17 M Increased by +12.41% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -3.82 M Decreased by -9.89% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -2.60 M Increased by +20.99% | Decreased by N/A% Decreased by N/A% |